The current financial score of Niagen Bioscience Inc is 9.12. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 29.79M, representing a year-over-year decrease of 4.28%, while its net profit experienced a year-over-year decrease of 73.32%.
The current valuation score of Niagen Bioscience Inc is 6.79. Its current P/E ratio is 12.85, which is 388.21% below the recent high of 62.72 and 59.68% above the recent low of 5.18.
The current earnings forecast score of Niagen Bioscience Inc is 8.67. The average price target is 12.08, with a high of 22.00 and a low of 8.50.
The current price momentum score of Niagen Bioscience Inc is 3.07. Currently, the stock price is trading between the resistance level at 3.24 and the support level at 2.85, making it suitable for range-bound swing trading.
The current institutional shareholding score of Niagen Bioscience Inc is 3.00. The latest institutional shareholding proportion is 38.95%, representing a quarter-over-quarter decrease of 23.33%. The largest institutional shareholder is James Simons, holding a total of 659.58K shares, representing 0.00% of shares outstanding, with 46.97% decrease in holdings.
The current risk assessment score of Niagen Bioscience Inc is 4.86. The company's beta value is 2.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.